FSHD Research Update Meeting
Feb 3, 2024 to Feb 3, 2024
Feb 3, 2024 to Feb 3, 2024
Posted by Friends of FSH Research on Jan 12, 2024
Fueling
DISCOvery
Join us at the Bellevue Hyatt just prior to our Annual Auction for an update on current FSHD research.
1:30 - 4:00 pm Seattle Time in the Maple Room, leaving time for those attending the auction to change, check in, get some champagne and munchies.
Join Zoom Meeting
https://us06web.zoom.us/j/82676171328?pwd=7o7t1twrLFdB6ntOQqh3JPlBjtLE25.1
Meeting ID: 826 7617 1328
Passcode: 810960
Speaker
Title & Time
Premi Haynes, PhD
Introduction
Scientific Advisor & Board Member for Friends of FSH Research
1:30 pm-1:35 pm
Jeff Chamberlain, PhD
Update on gene therapy
Chair of Scientific Advisory Board, Friends of FSH Research; President, American Society for Gene and Cell Therapy; Professor and McCaw Chair in Muscular Dystrophy ;Director, Sen. Paul D. Wellstone Muscular Dystrophy Specialized Research Center; Depts. Of Neurology, Medicine and Biochemistry, University of Washington School of Medicine, Seattle, WA
1:30 pm-1:35 pm
Stephen Tapscott, MD, PhD
Seattle Wellstone FSHD Clinical Study Molecular Markers of FSHD
Professor, Human Biology Division, Clinical Research Division; Fred Hutchinson Cancer Research Center; Dept of Neurology, University of Washington Seattle, WA
1:50 pm-2:05 pm
Seth Friedman, PhD
MRI data lake updates: to individual muscles and beyond
Manager of Innovation Imaging and Simulation Modeling, Seattle Children’s Hospital, Seattle, WA
2:05 pm-2:20 pm
Tessa Arends, PhD
Consequence of DUX4 expression in FSHD
Postdoctoral Research Fellow in the lab of Dr. Stephen Tapscott, Fred Hutchinson Cancer Center, Seattle, WA
2:20pm-2:35pm
Break
2:35 pm-2:45 pm
Jeffrey Statland, MD
TBD
Professor of Neurology; University of Kansas Medical Center, Kansas City, KS
2:45 pm-3:00 pm
Anthony D. Saleh, PhD
TBD
CEO, MiRecule, Inc.
3:00pm-3:15pm
Weston Miller, MD
EPI-321: A Potential Treatment for FSHD
CMO, Epic Bio
3:15pm-3:30pm
Christina Tysoe, PhD
Avidity Update: AOC 1020 and the FORTITUDE Study
Clinical Scientist, Avidity Biosciences
3:30pm-3:45pm
Ali Ozes, PhD
Targeting DUX4 with a first-in-class small molecule inhibitor
Founder, CEO & Board Member, Altay Therapeutics
3:45pm-4:00pm
Connect with us on social media